Zydus Cadila has received the final approval from the USFDA to market Pottassium Citrate ER tablets 5, 10 and 15 mEq used in the prevention of kidney stones.

The estimated sale in 2014 for potassium Citrate ER tablets is USD 131.7 million, as per IMS.

The group now has 94 approvals and has so far filed 239 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 11.8, or 1.08%, to trade at Rs 1,106.90. The total volume of shares traded was 1,128 at the BSE (10.47 a.m., Thursday).